Skip to content
Screener

BioMarin Pharmaceuticals BMRN Q1 2025 earnings

Reported May 1, 2025 · After market close

Revenue$745.1MMiss by $17.3M
EPS$1.13Beat by $0.19
Revenue estimate$762.4M
EPS estimate$0.94

Next report

Oct 26, 2026 (in a month)
Revenue estimate$1.0B
EPS estimate$1.35

Financials

Q1 2025

Income statement

See full
Revenue$745.1M+14.8%
Gross profit$593.6M+13.4%
Operating income$223.9M+153%
Net income$185.7M+109%
EPS (diluted)$0.95+107%

Balance sheet

See full
Cash & equivalents$1.0B+40.4%
Total debt$600.0M-62.4%
Total equity$5.8B+14.2%
Total assets$7.1B+4.0%

Cash flow

See full
Operating cash flow$174.4M+271%
CapEx$16.8M-35.8%
Free cash flow$157.6M+655%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$13.49B-18.2%
Enterprise value$13.04B-24.8%
P/E25.7×-54.5×
P/S4.6×-2.1×

Profitability

See full
Gross margin79.4%+0.5pp
Operating margin21%+12.4pp
Net margin17.8%+9.4pp
FCF margin21.2%—

Returns & leverage

See full
Return on equity9.6%+5.4pp
Debt / equity0.1×-0.2×
Current ratio5.5×+2.8×

Segments

By product

See full
VOXZOGO$213.8M+39.8%
VIMIZIM$188.3M-2.2%
NAGLAZYME$114.3M+8.2%
PALYNZIQ$93.3M+23.2%
ALDURAZYME$49.0M+38.9%

By segment

See full
Reportable Segment$745.1M+14.8%

FAQ

When did BioMarin Pharmaceuticals report Q1 2025 earnings?
BioMarin Pharmaceuticals (BMRN) reported Q1 2025 earnings on May 1, 2025 after market close.
What were BioMarin Pharmaceuticals's Q1 2025 revenue and EPS?
BioMarin Pharmaceuticals reported revenue of $745.1M and eps of $1.13 for Q1 2025.
Did BioMarin Pharmaceuticals beat estimates in Q1 2025?
Revenue missed the consensus estimate of $762.4M by $17.3M. EPS beat the consensus estimate of $0.94 by $0.19.
How did BioMarin Pharmaceuticals's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 14.8% from $648.8M a year earlier and eps grew 59.2% from $0.71.
Where can I find BioMarin Pharmaceuticals's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001048477-25-000049) and the 10-Q periodic report (0001048477-25-000051) directly on SEC EDGAR. The filing index links above go to sec.gov.